

3

con 3
2004-1129
1725-05

949

DIVISION DE NUEVAS CREACIONES

RADICACIÓN EXPEDIENTE No 03-039013

EL EXTRACTO DE LA PRESENTE SOLICITUD DE **PATENTE DE INVENCION**

PCT FUE PUBLICADO EN LA GACETA DE PROPIEDAD INDUSTRIAL No **544**

DE FECHA **30 DE SEPTIEMBRE DE 2004** EL TERMINO HABIL SEÑALADO

POR LA LEY EXPIRA EL **29 DE DICIEMBRE DEL 2004**

NOTA: Dentro del plazo de los seis (6) meses siguientes a partir de la fecha de publicación en la gaceta de Propiedad Industrial, deberá solicitar y cancelar el examen de patentabilidad so pena de que la solicitud caiga en abandono, de acuerdo con lo establecido en el Artículo 44 de la Decisión 486/2000.

SE PRESENTARON OPOSICIONES POR PARTE DE TERCEROS.

SI _____ NO ☒ _____

Bogotá D.C, SEPTIEMBRE DE 2007

877
948
D



PCT WELTORGANISATION FÜR GEISTIGES EIGENTUM
Internationales Büro
INTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)

(51) Internationale Patentklassifikation ⁶ : C07D 249/12, A01N 47/38	A1	(11) Internationale Veröffentlichungsnummer: WO 96/35680 (43) Internationales Veröffentlichungsdatum: 14. November 1996 (14.11.96)
(21) Internationales Aktenzeichen: PCT/EP96/01800 (22) Internationales Anmeldedatum: 30. April 1996 (30.04.96) (30) Prioritätsdaten: 195 17 505.0 12. Mai 1995 (12.05.95) DE (71) Anmelder (für alle Bestimmungsstaaten ausser US): BAYER AKTIENGESELLSCHAFT [DE/DE]; D-51368 Leverkusen (DE). (72) Erfinder; und (75) Erfinder/Anmelder (nur für US): MÜLLER, Klaus-Helmut [AT/DE]; Solfstrasse 19, D-40593 Düsseldorf (DE). KIRSTEN, Rolf [DE/DE]; Carl-Langhans-Strasse 27, D-40789 Monheim (DE). GESING, Ernst, R., F. [DE/DE]; Trillser Graben 4, D-40699 Erkrath (DE). KLUTH, Joachim [DE/DE]; Virneburgstrasse 69, D-40764 Langenfeld (DE). FINDEISEN, Kurt [DE/DE]; Dünfelder Strasse 28, D-51375 Leverkusen (DE). JANSEN, Johannes, R. [DE/DE]; Knipprather Strasse 47, D-40789 Monheim (DE). KÖNIG, Klaus [DE/DE]; Zum Hahnenberg 40, D-51519 Odenthal (DE). DREWES, Mark, Wilhelm [ZA/DE]; Goethestrasse 38, D-40764 Langenfeld (DE). DOLLINGER, Markus [DE/DE]; Burscheider Strasse 154b, D-51381 Leverkusen	(DE). SANTEL, Hans-Joachim [DE/DE]; Grünstrasse 9a, D-51371 Leverkusen (DE). (74) Gemeinsamer Vertreter: BAYER AKTIENGESELLSCHAFT; D-51368 Leverkusen (DE). (81) Bestimmungsstaaten: AU, BB, BG, BR, BY, CA, CN, CZ, HU, JP, KR, KZ, LK, MX, NO, NZ, PL, RO, RU, SK, UA, US, europäisches Patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Veröffentlicht Mit internationalem Recherchenbericht.	

(54) Title: SULPHONYLAMINO(THIO)CARBONYLTRIAZOLIN(THI)ONES WITH ARYLOXY OR ARYLTHIO SUBSTITUENTS

(54) Bezeichnung: HERBIZIDE SULFONYLAMINO(THIO)CARBONYLTRIAZOLIN(THI)ONE MIT ARYLOXY- ODER ARYLTHIO-SUBSTITUENTEN


(57) Abstract

The

in-
ven-
tion
con-
cerns
sulpho-
ny-

lamino(thio)carbonyltriazolin(thi)ones
of formula (I) in which Q¹ is

oxygen or sulphur, Q² is oxygen or sulphur, Q³ is oxygen or sulphur, R¹ is hydrogen, hydroxy, amino, alkylidenamino or an optionally substituted group from the series alkyl, alkenyl, alkynyl, alkoxy, alkylamino, dialkylamino, alkanoylamino, cycloalkyl, cycloalkylalkyl, cycloalkylamino, aryl and arylalkyl, R² is substituted aryl when Q³ is oxygen and R² is optionally substituted aryl when Q³ is sulphur, and R³ is an optionally substituted group from the series alkyl, arylalkyl, aryl and heteroaryl, plus salts of such compounds. The invention also concerns methods of preparing compounds of formula (I), intermediates for use in their preparation and the use of the compounds as herbicides.











(I)

(57) Zusammenfassung

Die Erfindung betrifft neue Sulfonylamino(thio)carbonyltriazolin(thi)one der Formel (I), in welcher Q¹ für Sauerstoff oder Schwefel steht, Q² für Sauerstoff oder Schwefel steht, Q³ für Sauerstoff oder Schwefel steht, R¹ für Wasserstoff, Hydroxy, Amino, Alkylidenamino oder für einen jeweils gegebenenfalls substituierten Rest aus der Reihe Alkyl, Alkenyl, Alkynyl, Alkoxy, Alkylamino, Dialkylamino, Alkanoylamino, Cycloalkyl, Cycloalkylalkyl, Cycloalkylamino, Aryl, Arylalkyl steht, R² für den Fall, daß Q³ für Sauerstoff steht, für substituiertes Aryl steht und für den Fall, daß Q³ für Schwefel steht, für gegebenenfalls substituiertes Aryl steht und R³ für einen jeweils gegebenenfalls substituierten Rest aus der Reihe Alkyl, Alkylalkyl, Aryl, Heteroaryl steht, und Salze von Verbindungen der Formel (I) sowie Verfahren und neue Zwischenprodukte zur Herstellung der Verbindungen (I) und deren Verwendung als Herbizide.

- 59 -

Tabelle 2: Beispiele für die Verbindungen der Formel (II)

Bsp.- Nr.	Q ¹	Q ³	R ¹	R ²	Schmelzpunkt (°C)
II-4	O	S	CH ₃		188
II-5	O	S	CH ₃		252
II-6	O	S	CH ₃		137
II-7	O	S	CH ₃		182
II-8	O	S	CH ₃		293
II-9	O	S			175
II-10	O	O	H		207

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification : Not classified		A2	(11) International Publication Number: WO 99/08501
			(43) International Publication Date: 25 February 1999 (25.02.99)
(21) International Application Number: PCT/US98/22568 (22) International Filing Date: 26 October 1998 (26.10.98) (30) Priority Data: 60/082,825 23 April 1998 (23.04.98) US (71) Applicants: DR. REDDY'S RESEARCH FOUNDATION [IN/IN]; 7-1-27, Ameerpet, Hyderabad, Andhra Pradesh 500 016 (IN). REDDY-CHEMINOR, INC. [US/US]; 66 South Maple Avenue, Ridgewood, NJ 07450 (US). (72) Inventors: LOHRAY, Vidya, Bhushan; 7-1-27 Ameerpet, Hyderabad, Andhra Pradesh 500 016 (IN). LOHRAY, Braj, Bhushan; 7-1-27 Ameerpet, Hyderabad, Andhra Pradesh 500 016 (IN). PARASELLI, Rao, Bheema; 7-1-27 Ameerpet, Hyderabad, Andhra Pradesh 500 016 (IN). RAMANUJAM, Rajagopalan; 7-1-27 Ameerpet, Hyderabad, Andhra Pradesh 500 016 (IN). CHAKRABARTI, Ranjan; 7-1-27 Ameerpet, Hyderabad, Andhra Pradesh 500 016 (IN). (74) Agents: CORD, Janet, I.; Ladas & Parry, 26 West 61st Street, New York, NY 10023 (US) et al.		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>Upon the request of the applicant, before the expiration of the time limit referred to in Article 21(2)(a). Without international search report and to be republished upon receipt of that report. Without classification; title and abstract not checked by the International Searching Authority.</i>	
(54) Title: NEW HETEROCYCLIC COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM (I)			
(57) Abstract The present invention relates to novel antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them. More particularly, the present invention relates to novel β-aryl-α-oxysubstituted alkylcarboxylic acids of general formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.			

1-5, 10-13 or 24 or a compound as claimed in claim 24 or a pharmaceutical composition as claimed in claims 25 and 26 to a patient in need thereof.

28. A method according to claim 27, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), useful as aldose reductase inhibitors, for improving cognitive functions in dementia and treating diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma or cancer.

29. A method according to claim 28, for the treatment or prophylaxis of disorders related to Syndrome X, which comprises administering an agonist of PPAR α and/or PPAR γ of formula (I).

30. A method of reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL and free fatty acids in the plasma comprising an effective amount of compound of formula (I) as defined in any one of claims 1-5, 10-13 or 24 or a pharmaceutical composition as claimed in claims 25 and 26 to a patient in need thereof.

31. A method of preventing or treating hyperlipemia, hypercholesteremia, hyperglycemia, osteoporosis, obesity, glucose intolerance, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering a compound of formula (I) as defined in any one of claims 1-5, 10-13 or 24 or a pharmaceutical composition as claimed in claim 25 and 26 in combination/concomittant with HMG CoA reductase inhibitors, fibrates, nicotinic acid, cholestyramine, colestipol or probucol which may be administered together or within such a period as to act synergistically together to a patient in need thereof.

32. A method according to claim 31, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidaemia, disorders related to Syndrome X such as hypertension, obesity, atherosclerosis, hyperlipidemia, coronary artery disease and other cardiovascular disorders, certain renal diseases including glomerulonephritis,